Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(12)
•••
Comment by MyKnighton Jul 15, 2019 9:19am
96 Views
Post# 29919938

RE:RE:RE:RE:RE:RE:RE:RE:Best Case Scenario

RE:RE:RE:RE:RE:RE:RE:RE:Best Case Scenario Best case scenario :
1.Phase 2 finish in aug/sept 2019. 
2. Start phase 3 by themself.(or with a partner) 
3. Bring the price to 0.40- 0.50
4. After we reach that price, RS  to bring the price over 4$, quickly.
5. Get in the big stock exchange
6. Edge fund company started to notice
7.phase 3 completed before end of 2020.... Not 3 years...
—— When fda approved insurance cover the treatment.

Then royalties and licence our product and start bringing money in 2020.
They can now produce....

Gw pharma we re all excited that the first cbd product brought 32 million in revenu since fda approval. (they charge 32 000$ per treatment)

GVHD is at a minimum 600 Millions market....and not sure  what the cost of treatment will be...

Then we re making money in 2020/2021.... all in royalties and licences would be my preference with a partner to supervised  and make sure we re not getting shorted illegally...


Then Kal-1816, come along with a company that is making a lot of money....


that would be my best scenario 




Bullboard Posts
Dealroom for high-potential pre-IPO opportunities